We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
-34.27%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72M
AUM Growth
-$34.4M
Cap. Flow
+$6.64M
Cap. Flow %
9.21%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$6.64M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICVX
1
DELISTED
Icosavax, Inc. Common Stock
ICVX
$20.1M 27.92%
3,510,228
– –
TRML
2
DELISTED
Tourmaline Bio
TRML
$13.2M 18.36%
293,261
– –
JSPR icon
3
Jasper Therapeutics
JSPR
$22.9M
$11.3M 15.68%
585,298
– –
VTYX
4
DELISTED
Ventyx Biosciences
VTYX
$11.1M 15.45%
910,306
– –
KZR
5
DELISTED
Kezar Life Sciences
KZR
$6.85M 9.51%
82,871
– –
HLVX
6
DELISTED
HilleVax
HLVX
$6.11M 8.48%
+558,923
New +$6.64M
ELEV
7
DELISTED
Elevation Oncology
ELEV
$3.32M 4.61%
2,370,142
– –

Similar funds

CCCPV
Castle Creek Capital Partners VI San Diego, California $55.9M AUM 7.91% 1-Year Est. Return
ACM
Aurelius Capital Management New York $55.2M AUM 124.79% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
NCFG
New Century Financial Group Princeton, New Jersey $56.3M AUM 16.99% 1-Year Est. Return
LAM
Lingohr Asset Management Duesseldorf, Germany $57.3M AUM 35.27% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
ITVII
IDG Technology Venture Investment IV Hong Kong $58.3M AUM 89.42% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Qiming U.S. Ventures Management's Q2 2022 Portfolio in Review

As of Q2 2022, Qiming U.S. Ventures Management held 7 positions worth $72M, down 32% from $106M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Qiming U.S. Ventures Management deployed $6.64M of net new capital in Q2 2022, opening 1 new position. Its largest new stake was HilleVax: 558,923 shares worth $6.11M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Qiming U.S. Ventures Management's largest Q2 2022 buy was HilleVax: 558,923 shares worth $6.11M.
  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $72M portfolio in Q2 2022.
  • Qiming U.S. Ventures Management opened 1 new position and closed 0 in Q2 2022.
  • Qiming U.S. Ventures Management's portfolio value fell 32% quarter-over-quarter to $72M.

Based on Qiming U.S. Ventures Management's 13F filing for Q2 2022, filed 22 Jul 2022.